Juan Ortiz, MD
General Practice · Tampa, FLNPI 1003354184
Payments from drug & device makers
Across 184 payments — averaging $23.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Lilly USA, LLC$414
- GSK$412
- Novo Nordisk$373
- Bayer$304
- Pfizer$268
- plus $1K from 22 others
What the payments were for
- Food & beverage$4,324100%
- Education$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 44 | $1,166 |
| Lilly USA, LLC | 17 | $414 |
| GSK | 12 | $412 |
| Novo Nordisk | 11 | $373 |
| Bayer | 15 | $304 |
| Pfizer | 16 | $268 |
| Otsuka America Pharmaceutical, Inc. | 8 | $251 |
| Johnson & Johnson | 10 | $172 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $136 |
| Novartis | 8 | $124 |
| AbbVie(2 entities) | 8 | $122 |
| Boehringer Ingelheim | 6 | $116 |
| Amgen | 5 | $83 |
| Scilex Pharmaceuticals Inc. | 1 | $65 |
| Dexcom, Inc. | 2 | $38 |
| Teva Pharmaceuticals USA, Inc. | 1 | $38 |
| Shield Therapeutics Inc | 2 | $37 |
| Biogen | 2 | $33 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $28 |
| Amarin Pharma, Inc. | 1 | $24 |
| Phadia US Inc. | 1 | $21 |
| Emergent Biosolutions Inc. | 1 | $20 |
| Lifescan, Inc. | 1 | $18 |
| Exact Sciences | 1 | $18 |
| Evoke Pharma, Inc. | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Vanda Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$490
- TRELEGY ELLIPTA$250
- REXULTI$122
- MOUNJARO$122
- Ozempic$120
How this compares
$4,343 in reported general payments places this provider in the 90th percentile of 6,901 general practice providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 201 | $219,827 |
| FarxigaDapagliflozin Propanediol | 154 | $145,717 |
| EliquisApixaban | 123 | $130,439 |
| JardianceEmpagliflozin | 105 | $122,878 |
| TrulicityDulaglutide | 82 | $80,138 |
| XareltoRivaroxaban | 104 | $72,068 |
| MounjaroTirzepatide | 53 | $64,445 |
| LinzessLinaclotide | 94 | $63,987 |
| CreonLipase/Protease/Amylase | 19 | $54,731 |
| TradjentaLinagliptin | 56 | $43,131 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 47 | $41,682 |
| JanumetSitagliptin Phos/Metformin Hcl | 37 | $40,276 |
| EntrestoSacubitril/Valsartan | 35 | $40,111 |
| RybelsusSemaglutide | 17 | $32,228 |
| VascepaIcosapent Ethyl | 36 | $25,429 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $373 | $252,055218 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Brilinta | $1,166 | $222,110292 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat, Stiolto Respimat, Spiriva Respimat | $116 | $208,323229 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $414 | $144,582135 claims |
| PfizerEliquis | $268 | $130,439123 claims |
| AbbVieLinzess, Creon | $122 | $118,717113 claims |
| Johnson & JohnsonXarelto, Invokana | $172 | $80,832117 claims |
| NovartisEntresto | $124 | $40,11135 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $412 | $27,75637 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,901 general practice providers in Florida.
Other general practice in Tampa
- Arnaldo Orellana MolinaTampa$2.5M
- Robert HannumTampa$1.8M
- Osvanny NodalTampa$1.1M
- Jose CardonaMiami$71M
- Lawrence GalitzMiami Gardens$42.5M
- Armando AcevedoMiami$15.2M
- Jorge AmayaMiami$14.2M
- Frank AlvarezHialeah$13.6M
- Hector RodriguezMiami$12.8M
- Eddie ArmasSouth Miami$12.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.